Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Kenneth B. Margulies, Silvio E. Inzucchi, Sanjiv J. Shah, Michael J. Muehlbauer et al.
Citations
21 citations
Journal
Circulation Heart Failure
Topics
Diabetes Treatment and Management
Field-Weighted Citation Impact (FWCI)
7.51
article
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Kenneth B. Margulies, Silvio E. Inzucchi, Sanjiv J. Shah, Michael J. Muehlbauer, Ali Javaheri, Sheryl L. Windsor, Lydia Coulter Kwee, Robert W. McGarrah, Svati H. Shah, David E. Lanfear, Senthil Selvaraj, Barry A. Borlaug, Andrew J. Sauer, Mansoor Husain, Kavita Sharma, Mikhail Kosiborod, Dalane W. Kitzman, Olga Ilkayeva, Guillermo E. Umpierrez, Christopher B. Newgard, Robert John Mentz, Darren K. McGuire, Philip G. Jones, Shachi Patel
article en
21 citations
Abstract
No abstract available for this paper.
Publication Tag
Circulation Heart FailureVol. 17(11)
Institutions
Northwestern University (US), Parkland Health & Hospital System (US), Mayo Clinic (US), Johns Hopkins University (US), Emory University (US), Duke University (US), Washington University in St. Louis (US), Hospital of the University of Pennsylvania (US), Johns Hopkins Medicine (US), Henry Ford Hospital (US), Yale University (US), Ted Rogers Centre for Heart Research (CA), Mayo Clinic in Arizona (US), Duke Medical Center (US), Saint Luke's Hospital (US), Wake Forest University (US), University of Missouri–Kansas City (US)
Funders
U.S. Department of Defense, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Alnylam Pharmaceuticals, Edwards Lifesciences, Boston Scientific Corporation, Cytokinetics, Dexcom, Tenax Therapeutics, Verily Life Sciences, Novo Nordisk, Vifor Pharma, Esperion Therapeutics, National Institutes of Health